CONTEXT: Marked elevations of 17-hydroxyprogesterone (17OHP) are characteristic of classic 21-hydroxylase deficiency (21OHD). Testing of 17OHP provides the basis for 21OHD diagnosis, although it suffers from several pitfalls. False-positive or false-negative results and poor discrimination of nonclassic 21OHD from carriers limit the utility of serum 17OHP and necessitate dynamic testing after cosyntropin stimulation when values are indeterminate. OBJECTIVE: The objective was to provide a detailed characterization of 21-carbon (C21) steroids in classic 21OHD, which might identify other candidate steroids that could be employed for the diagnosis of 21OHD. SETTING AND PARTICIPANTS: Patients (11 women, 10 men) with classic 21OHD and 21 sex- and age-matched controls seen in a tertiary referral center were studied. METHODS: C21 steroids in the peripheral sera from all subjects, as well as in media from cultured testicular adrenal rest tumor (TART) cells and normal adrenal (NA) cells, were analyzed using liquid chromatography/tandem mass spectrometry (10 steroids). Additionally, the dynamics of C21 steroid metabolism in TART and NA cells were assessed with radiotracer studies. RESULTS: Five C21 steroids were significantly higher in 21OHD patients: 17OHP (67-fold; P < .01), 21-deoxycortisol (21dF; 35-fold; P < .01), 16α-hydroxyprogesterone (16OHP; 28-fold; P < .01), progesterone (2-fold; P < .01), and 11β-hydroxyprogesterone (11OHP; not detected in controls; P < .01). The same steroids were the highest in media from TART cells relative to the NA cells: 11OHP, 58- to 65-fold; 21dF, 30- to 41-fold; 17OHP, 9-fold; progesterone, 9- to 12-fold; and 16OHP, 7-fold. CONCLUSION: Measurement of 16OHP and 11OHP along with 17OHP and 21dF by liquid chromatography/tandem mass spectrometry might comprise a biomarker panel to accurately diagnose all forms of 21OHD.
CONTEXT: Marked elevations of 17-hydroxyprogesterone (17OHP) are characteristic of classic 21-hydroxylase deficiency (21OHD). Testing of 17OHP provides the basis for 21OHD diagnosis, although it suffers from several pitfalls. False-positive or false-negative results and poor discrimination of nonclassic 21OHD from carriers limit the utility of serum 17OHP and necessitate dynamic testing after cosyntropin stimulation when values are indeterminate. OBJECTIVE: The objective was to provide a detailed characterization of 21-carbon (C21) steroids in classic 21OHD, which might identify other candidate steroids that could be employed for the diagnosis of 21OHD. SETTING AND PARTICIPANTS: Patients (11 women, 10 men) with classic 21OHD and 21 sex- and age-matched controls seen in a tertiary referral center were studied. METHODS:C21steroids in the peripheral sera from all subjects, as well as in media from cultured testicular adrenal rest tumor (TART) cells and normal adrenal (NA) cells, were analyzed using liquid chromatography/tandem mass spectrometry (10 steroids). Additionally, the dynamics of C21steroid metabolism in TART and NA cells were assessed with radiotracer studies. RESULTS: Five C21steroids were significantly higher in 21OHD patients: 17OHP (67-fold; P < .01), 21-deoxycortisol (21dF; 35-fold; P < .01), 16α-hydroxyprogesterone (16OHP; 28-fold; P < .01), progesterone (2-fold; P < .01), and 11β-hydroxyprogesterone (11OHP; not detected in controls; P < .01). The same steroids were the highest in media from TART cells relative to the NA cells: 11OHP, 58- to 65-fold; 21dF, 30- to 41-fold; 17OHP, 9-fold; progesterone, 9- to 12-fold; and 16OHP, 7-fold. CONCLUSION: Measurement of 16OHP and 11OHP along with 17OHP and 21dF by liquid chromatography/tandem mass spectrometry might comprise a biomarker panel to accurately diagnose all forms of 21OHD.
Authors: S Pang; W Murphey; L S Levine; D A Spence; A Leon; S LaFranchi; A S Surve; M I New Journal: J Clin Endocrinol Metab Date: 1982-09 Impact factor: 5.958
Authors: Richard J Auchus; Elizabeth O Buschur; Alice Y Chang; Gary D Hammer; Carole Ramm; David Madrigal; George Wang; Martha Gonzalez; Xu Steven Xu; Johan W Smit; James Jiao; Margaret K Yu Journal: J Clin Endocrinol Metab Date: 2014-04-29 Impact factor: 5.958
Authors: Mary H Bassett; Takashi Suzuki; Hironobu Sasano; Carlie J M De Vries; Patricia T Jimenez; Bruce R Carr; William E Rainey Journal: J Biol Chem Date: 2004-06-18 Impact factor: 5.157
Authors: R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Beatriz C Borges; David Garcia-Galiano; Sanseray da Silveira Cruz-Machado; Xingfa Han; Galina B Gavrilina; Thomas L Saunders; Richard J Auchus; Saher S Hammoud; Gary D Smith; Carol F Elias Journal: Endocrinology Date: 2017-09-01 Impact factor: 4.736
Authors: Juilee Rege; Aya T Nanba; Richard J Auchus; Jianwei Ren; Hwei-Ming Peng; William E Rainey; Adina F Turcu Journal: J Clin Endocrinol Metab Date: 2018-01-01 Impact factor: 5.958
Authors: Adina F Turcu; Aya T Nanba; Robert Chomic; Sunil K Upadhyay; Thomas J Giordano; James J Shields; Deborah P Merke; William E Rainey; Richard J Auchus Journal: Eur J Endocrinol Date: 2016-02-10 Impact factor: 6.664
Authors: Eric Gonzalez; Kevin M Johnson; Pradeep S Pallan; Thanh T N Phan; Wei Zhang; Li Lei; Zdzislaw Wawrzak; Francis K Yoshimoto; Martin Egli; F Peter Guengerich Journal: J Biol Chem Date: 2017-12-06 Impact factor: 5.157
Authors: James B Byrd; Amy E Rothberg; Robert Chomic; Charles F Burant; Robert D Brook; Richard J Auchus Journal: Cardiorenal Med Date: 2015-09-09 Impact factor: 2.041